Egalet Corporation (NASDAQ:EGLT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

(b) Jean-FranoisFormela, MD submitted his resignation from the
Board of Directors (the Board) of Egalet Corporation (the
Company) and all committees of the Board on which he served,
effective upon receipt by the Secretary of the Company, which
occurred on April4, 2017.

(d) On April8, 2017, the Board appointed Andrea Heslin Smiley and
Elaine Hochberg as directors of the Company. Ms.Smiley was
appointed to fill the vacancy created by Dr.Formelas resignation
and Ms.Hochberg was appointed to fill a vacancy created when the
size of the Board was expanded from seven to eight members. The
Board has not yet made a determination regarding the committees
on which Mss. Smiley and Hochberg will serve.

Ms.Smiley has served as President and CEO of VMS BioMarketing
since 2011. She joined VMS Biomarketing in 2008. Prior to joining
VMS BioMarketing, Ms.Smiley served in various positions at Eli
Lilly and Company. She serves on the boards of several nonprofit
corporations, including the Indiana Chapter of the Alzheimers
Association.

Ms.Hochberg has been the managing partner of Elaran, LLC, a
business strategy and management firm, since 2016. She served in
various positions of increasing responsibility at Forest
Laboratories, LLC from 1997 to 2014, including as Executive Vice
President – International, Strategic Planning and Government
Affairs from 2013 to 2014, as Executive Vice President US Sales
and Marketing from 2010 to 2013 and as Chief Commercial Officer
from 2007 to 2013. Prior to that, Ms.Hochberg served in various
roles at Wyeth-Ayerst Laboratories. She serves on the board of
Akcea Therapeutics,Inc., as well as the boards of several
nonprofit corporations.

Upon their appointment to the Board, each of Mss. Smiley and
Hochberg became entitled to receive an annual cash retainer in
the amount of $40,000, to non-employee director compensation
resolutions approved by the Compensation Committee of the Board
on November20, 2015. In addition, under those compensation
resolutions and to the Companys Amended and Restated 2013
Stock-Based Incentive Compensation Plan, each of Mss. Smiley and
Hochberg will be granted options to purchase $133,000 in value
based on the Black-Scholes value of the Companys common stock,
par value $.001 per share, effective on May1, 2017, which is the
first trading day of the month after the commencement of their
respective service as a director.

Additional information regarding each of Mss. Smileys and
Hochbergs appointment as a director is contained in the press
release attached hereto as Exhibit99.1.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

About Egalet Corporation (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Egalet Corporation (NASDAQ:EGLT) Recent Trading Information

Egalet Corporation (NASDAQ:EGLT) closed its last trading session down -0.02 at 4.47 with 166,945 shares trading hands.